Bugworks

Bugworks has developed a novel methodology to mitigate efflux mediated drug resistance and enable the entry of antibiotics into Gram negative pathogens; two key barriers that inhibited the development of the next generation of antibiotics. The company has validated a new paradigm altering antibiotic discovery strategy, yielding 5 novel antibacterial chemical series in 2 years that are now at clinical stages of deployment. Bugworks is the only Asian company to have won the prestigious US-government driven CARB-X grant (bestowed upon the top 5% of global innovations in the Antibiotics space)